Screener / SEC EDGAR /CIK 0001295947 /10-K filed May 14, 2026, compared with May 9, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Pharmaceuticals

Prestige Consumer Healthcare Inc. PBH

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. 10-K, Item 1

Headquarters
Tarrytown, NY
Next results
around Feb 4, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2026

Revenue of $1.1B through the costs to a net profit of $190.3M · income statement of the 10-K

28% operating margin
Revenue to Gross profit: $595.6MRevenue to Cost of revenue: $493.1MGross profit to Operating profit: $309.4MGross profit to Operating expenses: $286.2MOperating profit to Net profit: $190.3MOperating profit to Tax & other: $119.1M Revenue: $1.1B REVENUE $1.1B −4% Y/Y Gross profit: $595.6M · 55% margin GROSS PROFIT $595.6M 55% margin · −6% Y/Y Cost of revenue: $493.1M · 45% of revenue COST OF REVENUE $493.1M 45% of revenue Operating profit: $309.4M · 28% margin OPERATING PROFIT $309.4M 28% margin · −8% Y/Y Operating expenses: $286.2M · 26% of revenue OPERATING EXPENSES $286.2M 26% of revenue Net profit: $190.3M · 17% margin NET PROFIT $190.3M 17% margin · −11% Y/Y Tax & other: $119.1M · 11% of revenue TAX & OTHER $119.1M 11% of revenue
Gross profit $595.6M 55% margin · −6% Y/Y
Operating profit $309.4M 28% margin · −8% Y/Y
Net profit $190.3M 17% margin · −11% Y/Y
The full income statement, year by year

PBH among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -4.3%, above 5% of 154 peers (their median 10.5%) REVENUE GROWTH -4.3% · above 5% Gross margin: 52.5%, above 29% of 107 peers (their median 63.8%) GROSS MARGIN 52.5% · above 29% Operating margin: 25.0%, above 88% of 138 peers (their median 9.8%) OPERATING MARGIN 25.0% · above 88% Net margin: 13.3%, above 67% of 153 peers (their median 6.7%) NET MARGIN 13.3% · above 67% FCF margin: 18.4%, above 73% of 144 peers (their median 9.9%) FCF MARGIN 18.4% · above 73% Return on capital: 5.7%, above 24% of 89 peers (their median 9.2%) RETURN ON CAPITAL 5.7% · above 24%
PBH Peer median Below the median

What changed

11 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed May 14, 2026 against May 9, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +7.7% ($147.7M to $159.1M) vs revenue -4.3% ($1.1B to $1.1B), +12.0 pts apart
  • Receivables -1.2% ($194.3M to $191.9M) vs revenue -4.3% ($1.1B to $1.1B), +3.1 pts apart
9 more checks with nothing to note
  • Cash from operations $257.6M vs net income $190.3M (FY ending Mar 31, 2026)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Indefinite-Lived Tradename Impairment Assessments - Summer’s Eve and Monistat; Goodwill Impairment Assessment - North American Women’s Health Reporting Unit
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

11 paragraphs in Risk Factors that were not in the 10-K filed May 9, 2025. Quoted as filed.

All 11 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
    Heightened regulatory activity and expectations worldwide, particularly for sterile eye care products, have contributed to ongoing manufacturing disruptions and capacity constraints across the industry. These conditions have impacted, and we expect they will continue to impact for the foreseeable future, the availability of sterile eye…
  2. Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
    Regulatory authorities, including the Federal Trade Commission, have increasingly focused on the substantiation of marketing and advertising claims and have commenced enforcement actions against companies for failures to adequately substantiate such claims. As a result, we may face increased scrutiny of our marketing practices, and any…
  3. Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
    We and certain of our suppliers and customers have faced, and likely will continue to face evolving cybersecurity threats, including ransomware, malware, denial-of-service attacks, credential theft, business email compromise, phishing, social engineering (including AI-enabled impersonation), supply chain attacks and other attempts to…
  4. Item 1A · new paragraph · not in the 10-K filed May 9, 2025 10-K, ITEM 1A
    The use of artificial intelligence technologies presents operational, legal and regulatory risks.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025FY2026
Revenue$1.1B$1.1B$1.1B$1.1B
Net income−$82.3M$209.3M$214.6M$190.3M
Operating cash flow$229.7M$248.9M$251.5M$257.6M
Free cash flow$221.9M$239.4M$243.3M$246.4M

Revenue, FY2017 to FY2026

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.1B ▼ 4.3% in FY2026

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Prestige Consumer Healthcare Inc., Tarrytown, NY · from the 10-K filed May 14, 2026

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., “2026”) refers to our fiscal year ended March 31 of that year.

Headquarters
Tarrytown, NY
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
March 31
Last results
Nov 5, 2026

Email alerts

Sources

The 10-K filed May 14, 2026 (open at SEC), compared with the 10-K filed May 9, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PBH/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.